155 related articles for article (PubMed ID: 12500244)
1. Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy.
Ieiri N; Hotta O; Taguma Y
Am J Kidney Dis; 2003 Jan; 41(1):244-9. PubMed ID: 12500244
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of lipoprotein glomerulopathy in a daughter and a mother using niceritrol.
Hamatani H; Hiromura K; Kobatake K; Yoshida H; Kobayashi S; Yoneda N; Kayakabe K; Matsumoto T; Kuroiwa T; Ueki K; Nojima Y
Clin Exp Nephrol; 2010 Dec; 14(6):619-24. PubMed ID: 20842518
[TBL] [Abstract][Full Text] [Related]
3. Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy.
Arai T; Yamashita S; Yamane M; Manabe N; Matsuzaki T; Kiriyama K; Kanayama Y; Himeno S; Matsuzawa Y
Atherosclerosis; 2003 Aug; 169(2):293-9. PubMed ID: 12921981
[TBL] [Abstract][Full Text] [Related]
4. Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a patient with lipoprotein glomerulopathy.
Matsunaga A; Furuyama M; Hashimoto T; Toyoda K; Ogino D; Hayasaka K
Clin Exp Nephrol; 2009 Dec; 13(6):659-62. PubMed ID: 19603250
[TBL] [Abstract][Full Text] [Related]
5. Hereditary features, treatment, and prognosis of the lipoprotein glomerulopathy in patients with the APOE Kyoto mutation.
Hu Z; Huang S; Wu Y; Liu Y; Liu X; Su D; Tao Y; Fu P; Zhang X; Peng Z; Zhang S; Yang Y
Kidney Int; 2014 Feb; 85(2):416-24. PubMed ID: 24025644
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein glomerulopathy associated with psoriasis vulgaris: report of 2 cases with apolipoprotein E3/3.
Chang CF; Lin CC; Chen JY; Yang AH; Shiao MS; Kao JT; Yang WC
Am J Kidney Dis; 2003 Sep; 42(3):E18-23. PubMed ID: 12955707
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein glomerulopathy with markedly increased arterial stiffness successfully treated with a combination of fenofibrate and losartan: a case report.
Kato J; Okonogi H; Kanzaki G; Katsumata H; Nakada Y; Sagasaki M; Komine K; Ito K; Saito T; Matsunaga A; Tokutou K; Honda K; Tsuboi N; Yokoo T
BMC Nephrol; 2024 May; 25(1):171. PubMed ID: 38769490
[TBL] [Abstract][Full Text] [Related]
8. Topics in lipoprotein glomerulopathy: an overview.
Saito T; Matsunaga A; Ito K; Nakashima H
Clin Exp Nephrol; 2014 Apr; 18(2):214-7. PubMed ID: 24149835
[TBL] [Abstract][Full Text] [Related]
9. Lipoprotein glomerulopathy: significance of lipoprotein and ultrastructural features.
Saito T; Oikawa S; Sato H; Sato T; Ito S; Sasaki J
Kidney Int Suppl; 1999 Jul; 71():S37-41. PubMed ID: 10412734
[TBL] [Abstract][Full Text] [Related]
10. Plasma level and genetic variation of apolipoprotein E in patients with lipoprotein glomerulopathy.
Zhang B; Liu ZH; Zeng CH; Zheng JM; Chen HP; Zhou H; Li LS
Chin Med J (Engl); 2005 Apr; 118(7):555-60. PubMed ID: 15820086
[TBL] [Abstract][Full Text] [Related]
11. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases.
Saito T; Matsunaga A; Oikawa S
Am J Kidney Dis; 2006 Feb; 47(2):199-211. PubMed ID: 16431249
[TBL] [Abstract][Full Text] [Related]
12. A case report of youth-onset lipoprotein glomerulopathy with APOE Chicago mutation.
Liu Y; Cheng Y; Wen Y; Li C; Chen G; Li M
BMC Nephrol; 2024 Mar; 25(1):87. PubMed ID: 38448817
[TBL] [Abstract][Full Text] [Related]
13. A young Chinese man with nephrotic syndrome due to lipoprotein glomerulopathy.
Lui DTW; Lee ACH; Yap DYH; Chan GSW; Tan KCB
J Clin Lipidol; 2019; 13(2):251-253. PubMed ID: 30685233
[TBL] [Abstract][Full Text] [Related]
14. Identification of apolipoprotein E Guangzhou (arginine 150 proline), a new variant associated with lipoprotein glomerulopathy.
Luo B; Huang F; Liu Q; Li X; Chen W; Zhou SF; Yu X
Am J Nephrol; 2008; 28(2):347-53. PubMed ID: 18046082
[TBL] [Abstract][Full Text] [Related]
15. A case of lipoprotein glomerulopathy successfully treated with probucol.
Amenomori M; Haneda M; Morikawa J; Nishigaki I; Maeda S; Hidaka H; Kikkawa R; Shigeta Y
Nephron; 1994; 67(1):109-13. PubMed ID: 8052351
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis, histopathologic findings and treatment modalities of lipoprotein glomerulopathy: A review.
Cambruzzi E; Pêgas KL
J Bras Nefrol; 2019; 41(3):393-399. PubMed ID: 30421781
[TBL] [Abstract][Full Text] [Related]
17. Novel glomerular lipoprotein deposits associated with apolipoprotein E2 homozygosity.
Sakatsume M; Kadomura M; Sakata I; Imai N; Kondo D; Osawa Y; Shimada H; Ueno M; Miida T; Nishi S; Arakawa M; Gejyo F
Kidney Int; 2001 May; 59(5):1911-8. PubMed ID: 11318963
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein glomerulopathy may provide a key to unlock the puzzles of renal lipidosis.
Saito T; Matsunaga A
Kidney Int; 2014 Feb; 85(2):243-5. PubMed ID: 24487366
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological and genetic characteristics in Chinese patients with lipoprotein glomerulopathy.
Zhang B; Liu ZH; Zeng CH; Zheng JM; Chen HP; Li LS
J Nephrol; 2008; 21(1):110-7. PubMed ID: 18264944
[TBL] [Abstract][Full Text] [Related]
20. A case of apolipoprotein E Toyonaka and homozygous apolipoprotein E2/2 showing non-immune membranous nephropathy-like glomerular lesions with foamy changes.
Kato T; Ushiogi Y; Yokoyama H; Hara S; Matsunaga A; Muso E; Saito T
CEN Case Rep; 2019 May; 8(2):106-111. PubMed ID: 30701487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
